Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Hoth Therapeutics Inc (HOTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: HOTH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.98% | Avg. Invested days 42 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.11M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 2 | Beta 0.55 | 52 Weeks Range 0.58 - 2.79 | Updated Date 07/1/2025 |
52 Weeks Range 0.58 - 2.79 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.15% | Return on Equity (TTM) -98.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4165928 | Price to Sales(TTM) - |
Enterprise Value 4165928 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.4 | Shares Outstanding 13208900 | Shares Floating 13144588 |
Shares Outstanding 13208900 | Shares Floating 13144588 | ||
Percent Insiders 0.5 | Percent Institutions 2.31 |
Upturn AI SWOT
Hoth Therapeutics Inc
Company Overview
History and Background
Hoth Therapeutics, Inc. is a biopharmaceutical company focused on developing new therapies for unmet medical needs. Founded in 2017, it has focused on developing therapies for conditions like atopic dermatitis, also known as eczema.
Core Business Areas
- Dermatology: Focuses on developing novel therapies for dermatological conditions, primarily atopic dermatitis (eczema).
- Rare Diseases: Pursuing research and development for therapies addressing rare and underserved diseases.
Leadership and Structure
The leadership team comprises experienced professionals in biopharmaceuticals. Specific names and details may vary, but the general structure involves a CEO, CSO, and other key executive roles overseeing research, development, and operations. See https://ir.hoththerapeutics.com/corporate-information/management for updated list.
Top Products and Market Share
Key Offerings
- HT-001 (Atopic Dermatitis): A topical formulation under development for atopic dermatitis. Market share data is currently unavailable as it's in the development stages. Competitors include companies developing topical steroids, calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), and other novel treatments from companies like LEO Pharma, Incyte, and Sanofi/Regeneron (Dupixent).
- HT-ALZ (Alzheimer's Disease): A therapeutic for the treatment of Alzheimer's Disease. Market share data is currently unavailable as it's in the development stages. Competitors include companies developing other therapeutics for treatment of Alzheimers, such as Eli Lilly and Eisai's Lecanemab.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. The dermatology market is driven by increasing prevalence of skin conditions and demand for novel therapies. The rare disease market is gaining attention due to orphan drug incentives and unmet medical needs.
Positioning
Hoth Therapeutics is a relatively small player focused on niche areas. Its competitive advantage, if any, would stem from its specific technology or intellectual property related to its drug candidates.
Total Addressable Market (TAM)
The global atopic dermatitis market is projected to reach billions of dollars, offering substantial opportunity. The Alzheimer's market is significantly larger. Hoth's positioning depends on its clinical trial success and ability to secure partnerships or funding.
Upturn SWOT Analysis
Strengths
- Focused therapeutic pipeline on Atopic Dermatitis
- Targeting unmet medical needs
- Experienced management team (assumed)
Weaknesses
- Limited financial resources
- Early-stage drug development (high risk)
- Small market capitalization
- Dependence on external funding
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Orphan drug designation for rare diseases
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established players
- Difficulty securing funding
- Patent expiration
Competitors and Market Share
Key Competitors
- SNY
- REGN
- LLY
- ESALY
Competitive Landscape
Hoth faces significant competition from larger, well-established pharmaceutical companies with greater resources. Its success hinges on innovation and successful clinical trial results.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its early stage. Future growth depends on successful clinical trials and commercialization.
Future Projections: Future projections are highly speculative and depend on clinical trial outcomes and market adoption. Analyst estimates will provide greater fidelity.
Recent Initiatives: Recent initiatives focus on advancing its drug candidates through clinical trials and securing funding.
Summary
Hoth Therapeutics is a small, early-stage biopharmaceutical company focused on developing treatments for unmet medical needs. Its success is highly dependent on positive clinical trial results and securing partnerships or funding. Its limited financial resources and intense competition are significant challenges. The company needs to achieve clinical milestones to increase investor confidence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. It is essential to conduct thorough due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hoth Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-02-15 | Founder, President, CEO & Chairman Mr. Robb Knie | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://hoththerapeutics.com |
Full time employees 2 | Website https://hoththerapeutics.com | ||
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.